Technical Analysis for BCYC - Bicycle Therapeutics plc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 24.20 | 3.20% | 0.75 |
Earnings due: May 2
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 50 DMA | Bullish | 0.00% | |
BB Squeeze Ended | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Up 4 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
50 DMA Resistance | Bearish | 3.20% | |
Shooting Star Candlestick | Bearish | 3.20% | |
Bollinger Band Squeeze | Range Contraction | 3.20% | |
BB Squeeze + Upper Band Touch | Range Contraction | 3.20% |
Alert | Time |
---|---|
Up 5% | about 9 hours ago |
Up 1 ATR | about 9 hours ago |
Rose Above Previous Day's High | about 9 hours ago |
60 Minute Opening Range Breakout | about 10 hours ago |
Up 3% | about 10 hours ago |
Get a Trading Assistant
- Earnings date: 05/02/2024
Bicycle Therapeutics plc Description
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Disease Immunology Oncology Tumor Ophthalmology Hematology Immune Checkpoint Cancer Research Search Technology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 28.9 |
52 Week Low | 12.54 |
Average Volume | 388,607 |
200-Day Moving Average | 20.29 |
50-Day Moving Average | 23.98 |
20-Day Moving Average | 22.85 |
10-Day Moving Average | 23.22 |
Average True Range | 1.21 |
RSI (14) | 57.81 |
ADX | 18.77 |
+DI | 23.29 |
-DI | 13.84 |
Chandelier Exit (Long, 3 ATRs) | 21.32 |
Chandelier Exit (Short, 3 ATRs) | 25.25 |
Upper Bollinger Bands | 24.21 |
Lower Bollinger Band | 21.48 |
Percent B (%b) | 1.0 |
BandWidth | 11.97 |
MACD Line | -0.02 |
MACD Signal Line | -0.17 |
MACD Histogram | 0.1493 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 26.20 | ||||
Resistance 3 (R3) | 26.15 | 25.43 | 25.87 | ||
Resistance 2 (R2) | 25.43 | 24.92 | 25.46 | 25.76 | |
Resistance 1 (R1) | 24.82 | 24.60 | 25.12 | 24.87 | 25.65 |
Pivot Point | 24.10 | 24.10 | 24.25 | 24.12 | 24.10 |
Support 1 (S1) | 23.48 | 23.59 | 23.79 | 23.53 | 22.75 |
Support 2 (S2) | 22.76 | 23.27 | 22.79 | 22.64 | |
Support 3 (S3) | 22.15 | 22.76 | 22.53 | ||
Support 4 (S4) | 22.20 |